Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.68 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | TERF2 | Q15554 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | TERF2IP | Q9NYB0 | 3/20 | 0.37 |
| ▸ | FCGRT | P55899 | 2/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25622799 | 0.93 | KDM1A (0.72) | KDM1ARCOR1KEAP1NFE2L2TERF2 | |
| SCHEMBL25623302 | 0.82 | KDM1A (0.65) | KDM1ARCOR1TERF2IPSSTR2SSTR4 | |
| SCHEMBL21504244 | 0.82 | KDM1A (0.88) | KDM1ARCOR1TERF2F11TERF2IP | |
| SCHEMBL21474043 | 0.82 | KDM1A (0.88) | KDM1ARCOR1TERF2F11TERF2IP | |
| SCHEMBL25623330 | 0.82 | KDM1A (0.64) | KDM1ARCOR1F11TERF2IPSSTR2 | |
| Polymyxin B2 SCHEMBL534885 | 0.81 | KDM1A (1.00) | KDM1ARCOR1TERF2F11TERF2IP | |
| Polymyxin B2 SCHEMBL15887064 | 0.81 | KDM1A (1.00) | KDM1ARCOR1TERF2F11TERF2IP | |
| SCHEMBL16426297 | 0.81 | KDM1A (0.88) | KDM1ARCOR1KEAP1TERF2TERF2IP | |
| SCHEMBL21335145 | 0.81 | KDM1A (0.88) | KDM1ARCOR1KEAP1TERF2TERF2IP | |
| Desfa-[Dab1]Polymyxin B SCHEMBL29354296 | 0.81 | KDM1A (0.86) | KDM1ARCOR1KEAP1TERF2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | KDM1A 4789/4885RCOR1 4863/4885KEAP1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.